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The diagnostic accuracy and utility of
a B-type natriuretic peptide test in a




National guidelines suggest the use of natriuretic peptides
in suspected heart failure but there have been no studies
comparing assays in primary care.
Aim
To test and compare the diagnostic accuracy and utility of
B-type natriuretic peptide (BNP) and N-terminal B-type
natriuretic peptide (NT proBNP) in diagnosing heart failure
due to left ventricular systolic dysfunction in patients with
suspected heart failure referred by GPs to one-stop
diagnostic clinics.
Design of study
Community cohort, prospective, diagnostic accuracy study.
Setting
One-stop diagnostic clinics in Darlington Memorial and
Bishop Auckland General Hospitals and general practices
in South Durham.
Subjects
Two hundred and ninety-seven consecutive patients with
symptoms and signs suggestive of heart failure referred
from general practice.
Method
The study measured sensitivity, specificity, positive and
negative predictive values (PPV, NPV), and area under
receiver operating characteristic curve for BNP (near patient
assay) and NT proBNP (laboratory assay) in diagnosis of
heart failure due to left ventricular systolic dysfunction. The
NPV of both assays was determined as a potential method
of reducing the number of referrals for echocardiography.
Results
One hundred and fourteen of the 297 patients had left
ventricular systolic dysfunction (38%). At the manufacturer’s
recommended cut-off of 100 pg/ml BNP gave a NPV of
82%. BNP performed better at a cut-off of 40 pg/ml with a
NPV of 88%. At a cut-off of 150 pg/ml, NT proBNP gave a
NPV of 92%. Using cut-offs of 40 pg/ml and 150 pg/ml for
BNP and NT pro-BNP, respectively, could have prevented
24% and 25% of referrals to the clinic, respectively.
Conclusions
In this setting, NT pro-BNP performed marginally better
than BNP, and would be easier to use practically in
primary care. A satisfactory cut-off has been identified,
which needs validating in general practice. NT pro-BNP
could be used to select referrals to a heart failure clinic or
for echocardiography. This process needs testing in real-
life general practice.
Keywords
diagnosis; heart failure; natriuretic peptides.
INTRODUCTION
Heart failure is an increasing public health problem
that is largely managed in primary care.1 Diagnosis of
heart failure in patients presenting to general practice
is difficult, and may be incorrect in up to 70% of
cases.1–3 Echocardiography is currently considered to
be the investigation of choice for confirming left
ventricular systolic dysfunction. It is, however, not
uniformly available to all GPs, and may be an
expensive option for a first-line investigation.4–6 Even
if open access echocardiography is available its use
is variable, and many GPs have difficulties with
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interpretation of the results.4 Furthermore, the
capacity for performing the test is limited by lack of
availability of suitably trained technicians and
cardiologists to give a clinical interpretation of
results. Observational studies of open access
echocardiography services have shown that only
14–23% of patients referred have left ventricular
systolic dysfunction.3
B-type natriuretic peptide (BNP) is one of a family
of structurally similar peptide hormones. The major
site of BNP production is the left ventricle.7 Cleavage
of the precursor protein (proBNP) produces BNP,
which causes diuresis, natriuresis, vasodilatation
and smooth muscle relaxation, and the biologically
inactive peptide N-terminal BNP (NT proBNP).8 Both
are readily detectable in plasma and rise with
increased ventricular and atrial stretch and pressure
overload.7 Plasma levels are raised in heart failure,
rising in line with severity and New York Heart
Association functional class.9,10
It has been proposed that BNP or NT proBNP,
tests that can be performed using venous blood,
can be used by GPs to identify patients with heart
failure.11–13 Small, single-centre studies have
suggested that BNP or NT proBNP has
reproducible value as a test to rule out heart failure
due to left ventricular systolic dysfunction and to
potentially preselect patients for referral for
echocardiography.14–16 However, other studies have
questioned the accuracy of BNP in excluding heart
failure.17–19 Most studies used ‘in house’ 
assays and echocardiography, radionuclide
ventriculography or cardiac catheterisation as the
gold standard comparison, and examined selected
groups undergoing these investigations, which
were not representative of ‘all comers’ presenting
to general practice.
In late 2001 two assays became commercially
available, a point-of-care BNP fluorescence
immunoassay using the Biosite Triage System
(Biosite Diagnostics, Velizy, France) and an
automated laboratory ECLIA assay NT proBNP
system developed from a standard microtitre plate
system from Roche Diagnostics and run on the
Elecys analyser.
Both companies presented assay reference
ranges based on 97.5 percentiles in healthy
volunteers up to the age of 65 years. As the average
age of patients with heart failure is around 75 years,
this presented difficulties in use of the assays in our
population of patients with suspected heart failure.
There have been no comparative studies of the two
assays in patients suspected by their GPs of having
heart failure. Our primary study aim was to test and
compare the diagnostic accuracy and utility of BNP
and NT proBNP in diagnosing heart failure due to
left ventricular systolic dysfunction in patients with
suspected heart failure, referred by GPs to one-stop
diagnostic clinics.
METHOD
All 109 local GPs from 23 Darlington and Dales
practices were invited to refer patients with
symptoms and signs suggestive of heart failure to
a one-stop diagnostic clinic within their local
hospital.20 All practices covering a population of
190 000 patients agreed to participate, and 94 GPs
referred at least one patient to the clinics. The 15
GPs who did not refer did not differ from the 94
who did refer on the basis of age, sex,
geographical location, ethnicity, practice
partnership size, or length of time in practice.
Practices received an educational session on
current diagnosis and management of heart failure
from study clinicians and were given a locally
produced guideline on the diagnosis and
management of heart failure due to left ventricular
systolic dysfunction. A referral template was issued
to all GPs and their secretaries. The study ran over
a 12-month period.
All patients referred were clinically assessed by
clinicians with routine biochemistry, haematology,
chest X-ray and 12-lead electrocardiogram (ECG)
results available. Spirometry was conducted where
considered appropriate.
Sampling for BNP and NT proBNP
Venous blood samples were drawn by clinicians
under standard clinic conditions. For the triage BNP
assay, whole blood was drawn into an EDTA tube
and the sample assayed within 1 hour. For the
Roche Diagnostics NT proBNP assay, the sample
was taken into vacutainer tubes containing a
sample-separating gel and placed on ice. The
sample was transferred to the lab where it was spun,
separated and frozen at -20°C. Samples were then
assayed in batches using the Elecys analyser with
laboratory staff blinded to the clinical assessments.
How this fits in
Small, single-centre studies have suggested that B-type natriuretic peptide
(BNP) or N-terminal BNP (NT proBNP) has reproducible value as a test to rule
out heart failure due to left ventricular systolic dysfunction. Despite inclusion in
national guidelines, uptake of BNP or NT proBNP use has been slow in the
NHS. This is the first study, using consecutive patients referred from primary
care to one-stop diagnostic clinics that has compared a point-of-care assay of
BNP with a laboratory NT proBNP assay and demonstrated high negative
predictive value for both methods. We have identified suitable cut-offs for BNP
and NT proBNP in a patient group representative of patients suspected by GPs
of having heart failure, that could be used in primary care.
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The results were not used by clinicians in diagnostic
or management decision making. Quality controls
were carried out for both BNP and NT proBNP
assays before each run of assays.
Analysis
Concentrations of BNP and NT proBNP both
exhibited skewed distributions and were log
transformed before analysis. The diagnostic
performance of the assays were assessed using
receiver operating characteristic (ROC) curves,
formed by plotting sensitivity on the y axis and 1-
specificity on the x axis for all possible cut-off values
of each diagnostic test.21
In addition to the area under the curve (AUC), we
identified the cut-off value that maximised sensitivity
without unacceptable loss of specificity, ensuring
high negative predictive values.
The McNemar test was used to assess the
significance of differences between sensitivity and
specificity. Differences between AUCs were tested
using the method developed by Hanley and
McNeil.21, 22
Echocardiography and electrocardiography
Full standard echocardiography was performed and
reported by British Society of Echocardiography-
accredited clinical physiologists blinded to the
clinical details, clinical assessment and BNP/NT
proBNP results. Siemens Sequoia C256 and GE Vivid
7 echocardiogram machines were used at Bishop
Auckland and Darlington Memorial hospitals
respectively. Left ventricular function was assessed
by ‘eyeball’ assessment, by left ventricular ejection
fraction calculated by Simpson’s rule, and by wall
motion index using the American Society of
Echocardiography 16 segment model.23 Doppler
studies were also carried out and other cardiac
abnormalities that may have led to breathlessness or
a raised BNP/NT proBNP result were documented.
Fifteen per cent of echocardiograms were
independently assessed by a cardiologist as a
measure of quality control. Left ventricular systolic
dysfunction was defined as mild, moderate or
severe by ‘eyeball’ assessment (n = 114).24 Ejection
fraction was measured in patients in sinus rhythm if
adequate images were obtained and left ventricular
ejection fraction <0.40 was considered to represent
left ventricular systolic dysfunction (n = 67).25 A wall
motion index of >1.2 was taken to be abnormal
(n = 66). As it was not possible to measure ejection
fraction or wall motion index in all subjects,
clinicians diagnosed heart failure due to left
ventricular systolic dysfunction if one or more
parameter was abnormal.
ECGs were reported by two doctors as being
either normal or abnormal using the Minnesota
criteria.26
RESULTS
Three hundred and five consecutive patients
referred by their GPs to one-stop diagnostic clinics
at two hospital sites (Darlington Memorial and
Bishop Auckland General) were invited to
participate.20 Two hundred and ninety-seven patients
gave informed consent to be included, and eight
patients either declined study entry or were
considered incapable of giving informed consent.
Left ventricular Non-left ventricular
systolic dysfunction systolic dysfunction
patients (n = 114)a patients (n = 183) P values
Mean age (years) 73.5 74.0 nsb
Age range 34–94 43–94 ns
Sex, % male (n) 47 (54) 30 (55) <0.005
Diuretics, % (n) 70 (80) 63 (115) ns
ACE inhibitor or angiotensin II 
receptor blocker, % (n) 46 (53) 33 (60) <0.05
β-blocker, % (n) 18 (20) 21 (39) ns
Hypertension, % (n) 27 (31) 39 (71) <0.05
Ischaemic heart disease, % (n) 33 (38) 27 (49) ns
Previous myocardial infarction, % (n) 24 (27) 7 (12) <0.0001
Atrial fibrillation, % (n) 25 (29) 15 (27) <0.05
Diabetes, % (n) 8 (9) 10 (18) ns
Chronic obstructive pulmonary disease, % (n) 19 (22) 26 (47) ns
aNumber of patients. bLeft ventricular systolic dysfunction (LVSD) and non-LVSD patients not significantly different at 5% level.
Table 1. Baseline patient characteristics.
One hundred and fourteen patients (38%) had left
ventricular systolic dysfunction. Table 1 lists the
differences in baseline characteristics/
demographics of the left ventricular systolic
dysfunction and non-left ventricular systolic
dysfunction populations. Significantly more patients
in the left ventricular systolic dysfunction group
were male, were receiving angiotensin-converting
enzyme (ACE) inhibitors, had previous myocardial
infarction, or had atrial fibrillation, reflecting
individuals with high cardiovascular risk factors for
development of left ventricular systolic dysfunction.
Significantly more patients with hypertension did
not have left ventricular systolic dysfunction.
However, many of these had left ventricular
hypertrophy and diastolic dysfunction, and would
have been classified in other studies as having
heart failure with preserved systolic function.27
These conditions have been shown to raise
natriuretic peptide levels.28,29
All 297 patients had a natriuretic assay, but due to
technical reasons only 263 BNP and 273 NT
proBNP assays were completed. These reasons
included malfunction of the triage machine and
supply problems with diagnostic kits. This was
random and was not related to the presence or
severity of heart failure. Figure 1 shows the ROC
curves for both assays. Table 2 lists the areas under
the ROC curves for both assays by sex. Differences
in area between BNP and NT proBNP were not
statistically significant.
We selected a range of cut-off points to optimise
the test performances. For BNP we found the best
test performance and highest negative predictive
value (NPV) was at 40 pg/ml. For NT proBNP the
optimum value was 150 pg/ml. During the period of
study the manufacturers made cut-off
recommendations: Biosite (BNP) recommend
100 pg/ml and Roche diagnostics (NT proBNP)
recommend 125 pg/ml for both sexes in the US,
and 100 pg/ml and 150 pg/ml for males and
females respectively in Europe and the UK. Table 3
compares the NPV for both BNP and NT proBNP
using the recommended cut-offs with our own
results.
Table 4 shows the overall performance
characteristics of the two assays at our chosen cut-
off. The differences between BNP and NT proBNP
were not statistically significant. The cut-off points
of 40 pg/ml for BNP and 150 pg/ml for NT proBNP
both offer a high NPV of (0.88 and 0.92 respectively)
but specificity is relatively poor (0.38 and 0.40
respectively). However, 61% of patients with false-
positive results (38% of total patients) had other
significant cardiac or related abnormalities that
could have raised natriuretic peptide levels. These
Left ventricular systolic









aDifferences between BNP and NT proBNP were not
significant at the 5% level. ROC = receiver operator
characteristic.
Table 2. Area under ROC curve.
Peptide Cut-off point (pg/ml) NPV (95% CI)
BNP all 40 0.88 (0.80 to 0.96)
BNP All 100 0.82 (0.76 to 0.89)
NT proBNP all 125 0.92 (0.85 to 0.99)
NT proBNP all 150 0.92 (0.86 to 0.98)
NT proBNP male 100 0.89 (0.74 to 1.00)
NT proBNP female 150 0.94 (0.88 to 1.00)
NPV = negative predictive value.
Table 3. Negative predictive values at different cut-off
points.
Cut-off point Sensitivitya Specificitya PPVa NPVa
Peptide (pg/ml) (95% CI) (95% CI) (95% CI) (95% CI)
BNP 40 0.92 0.38 0.49 0.88
(0.87 to 0.97) (0.30 to 0.45) (0.42 to 0.57) (0.80 to 0.96)
NT proBNP 150 0.94 0.40 0.48 0.92
(0.90 to 0.99) (0.33 to 0.47) (0.41 to 0.55) (0.86 to 0.98)
aDifferences between BNP and NT proBNP were not significant at the 5% level. PPV = positive
predictive value. NPV = negative predictive value.
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Sensitivity Specificity PPV NPV
(95% CI) (95% CI) (95% CI) (95% CI)
0.82 0.58 0.55 0.83 
(0.74 to 0.89) (0.51 to 0.65) (0.47 to 0.62) (0.77 to 0.90)
PPV = positive predictive value. NPV = negative predictive value.
Table 5. Utility of the ECG in diagnosing left ventricular
systolic dysfunction by ‘eyeball’ assessment.
Original Papers
included left ventricular hypertrophy (n = 37),29 atrial
fibrillation (n = 17),30 mitral regurgitation (n = 17),
pulmonary hypertension (n = 17), diastolic
dysfunction (n = 14),28 aortic stenosis (n = 3),31 aortic
regurgitation (n = 2), atrial flutter (n = 2), right
ventricular hypertrophy (n = 2), cardiac amyloidosis
(n = 1), lupus and paraproteinaemia,
paraproteinaemia (n = 1), lung carcinoma (n = 1),
and cor pulmonale (n = 1).32 There were some
patients who had more than one of these
pathologies co-existing.
DISCUSSION
Summary of main findings
This is the first study, using consecutive patients
referred from primary care to one-stop diagnostic
clinics that has compared a point-of-care assay of
BNP with a laboratory NT proBNP assay and
demonstrated high NPV for both methods. The
patient group was representative of patients
suspected by their GPs of having heart failure.
Comparison with existing literature
The definition of heart failure due to left ventricular
systolic dysfunction varies between mortality
studies, and between specialist guideline
bodies.12,13,25,33 All guidelines suggest
echocardiography as the gold standard for
confirmation of left ventricular systolic
dysfunction.12,13 However, it is not always possible
to measure left ventricular ejection fraction,
especially in patients with obesity or chronic
obstructive pulmonary disease. In this situation,
‘eyeball’ assessment of left ventricular function has
been shown to be an accurate measure.24 This is
often a ‘real-life’ assessment technique employed
by experienced clinical physiologists and we felt it
important to conduct this study using this measure.
This is the first study to compare BNP and NT
proBNP against this standard, and demonstrate
high negative predictive values for ruling out left
ventricular systolic dysfunction.
Nine patients were false negatives, where BNP or
NT proBNP were below the cut-off points. All were
on cardio-active therapy (nine on diuretics, three
on ACE inhibitors and one on a β-blocker) which
could have lowered natriuretic peptide levels.34–36 If
natriuretic peptide assays were readily available
such patients would have been tested before
starting treatment. We are not yet at this stage in
the NHS, largely because there are unanswered
questions and funding issues around the use of
natriuretic peptides in primary care. It would not
have been ethical to stop treatment before
assaying patients, due to the risk of inducing
decompensated heart failure. However, we should
be reassured that individuals with low natriuretic
peptide levels have a good prognosis and most
were on appropriate therapy already.37,38
Since our study was initiated, Biosite has
suggested a cut-off point of 100 pg/ml for ruling out
heart failure. Our results show that this gave a NPV
of 82% compared to 88% at 40 pg/ml. Roche
diagnostics suggest cut-offs of 125 pg/ml for both
sexes in the US, but 100 pg/ml for males and
150 pg/ml for females in Europe and the UK. Our
results showed a NPV of 92% at 125 pg/ml, 89%
for males at 100 pg/ml, 94% for females at 150
pg/ml, and 92% for both sexes at a 150 pg/ml cut-
off (Table 3). Although Biosite suggests a cut-off of
100pg/ml our figures suggest that 40 pg/ml is a
better cut-off and Val-HeFT data suggest that a
BNP >40 pg/ml is associated with increased all-
cause mortality.39 In this study 13 patients with BNP
levels between 40 and 100 pg/ml who had left
ventricular systolic dysfunction would have been
denied evidence-based therapy.
Although point-of-care BNP may be useful when
a rapid result is needed, for example in the
emergency department or medical assessment unit,
it is likely to be impractical in general practice.40
Furthermore, it would not be practical for individual
or even groups of practices to own a Biosite Triage
machine costing around £2000; each test is costly
at around £15 each, kit shelf lives are short, and
performing quality controls is not a familiar task for
GPs. Laboratory assays are simple and familiar to
GPs, samples are stable at room temperature for up
to 72 hours, and quality controls are stringent.41 This
makes the laboratory assay an ideal test for use in
general practice.
Using cut-offs of 40 pg/ml and 150 pg/ml for BNP
and NT pro-BNP, respectively, could have
prevented 24% and 25% of referrals to the clinic,
respectively. This could potentially free up valuable
echocardiography capacity and clinician time in a
healthcare system in which the availability of both is
limited.
Guidelines and National Institute for Health and
Clinical Excellence guidance for the diagnosis and
management of heart failure due to left ventricular
systolic dysfunction suggest that if an ECG is
normal then left ventricular systolic dysfunction is
very unlikely, with a NPV of 97% in some studies.42
However, a NPV of 83% in this study suggests that
significant left ventricular systolic dysfunction can
be present in the presence of a normal ECG. If
current guidance had been adhered to in referral of
patients for echocardiography 18% (n = 21) of
patients with left ventricular systolic dysfunction
would have been missed. Previous studies that
suggested a normal ECG effectively ruled out left
ventricular systolic dysfunction may not have been
representative of the type of patients referred by
GPs with suspected heart failure.42 In this study
BNP and NT proBNP both performed better than
ECG in selection of patients for further assessment
of left ventricular function.
Despite inclusion in guidelines, uptake of BNP or
NT proBNP use has been slow in the NHS.12
Clinicians and primary care trusts still harbour
concerns about appropriate cut-offs, the extra cost
of BNP assays, lack of expedient referral pathways
for patients with a raised BNP level, and absence of
cost–benefit/effectiveness data.
Wright and colleagues demonstrated in a small
randomised controlled trial that NT proBNP
measurement significantly improves the diagnostic
accuracy of heart failure by GPs over and above
customary clinical review.43 However, this was a trial
situation, and is not necessarily representative of UK
GPs using NT proBNP in patients with suspected
heart failure and then deciding whether or not to
refer for echocardiography.
Strengths and limitations of the study
Consecutive patients referred to the clinics from
primary care were studied, hence reducing
selection bias. However, we did not study practices
to check whether there were any patients not being
referred to clinics. Since most GPs know that
echocardiography is needed for patients with
suspected heart failure and that the clinics are well
advertised, we feel it is likely that we captured all
the patients GPs worried about. Measurement bias
was reduced by utilising the same high-quality
echocardiography equipment operated by British
Society of Echocardiography-accredited cardiac
physiologists, reported to a uniform standard and
quality checked by one cardiologist. Disease
progression bias was reduced by all tests being
taken at a one-stop diagnostic clinic.
Thirty-eight per cent is an unexpectedly high
prevalence rate for left ventricular systolic
dysfunction in this population, and it is possible that
selection of patients was influenced by the education
sessions given to practices. This may have an impact
on the generalisability of this study.
These diagnostic values have been derived in one
cohort, but require validation in a second cohort
with different subjects and clinicians.
Implications for clinical practice and future
research
Further research studying the use of BNP or NT
proBNP, with or without electrocardiography, as
screening tests in patients with suspected heart
failure in an everyday NHS primary care
environment is urgently needed. A cut-off point of
150 pg/ml for NT proBNP could be used to select
referrals to a one-stop diagnostic clinic or for
echocardiography, but this process needs testing in
‘real-life’ general practice. GPs would have NT
proBNP available to use in triage of patients with
symptoms and signs suggestive of heart failure. An
assay result equal to or more than 150 pg/ml would
prompt GPs to refer for echocardiography. An assay
result of less than 150 pg/ml would effectively rule
out heart failure and prompt the GP to seek an
alternative cause for the patient’s symptoms and
signs. This would test the validity of this cut-off and
provide cost–benefit data to inform further use of
NT proBNP in primary care.
Such a future validation study could also recruit
GPs with and without the educational programme to
see whether this has an effect on diagnostic pick up
rates and appropriate referral for echocardiography.
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